{"id":2686,"date":"2019-10-16T14:50:55","date_gmt":"2019-10-16T04:50:55","guid":{"rendered":"https:\/\/orthocell.com\/us\/?p=2686"},"modified":"2021-10-21T14:53:24","modified_gmt":"2021-10-21T04:53:24","slug":"australias-orthocell-ready-to-file-on-interim-celgro-data","status":"publish","type":"post","link":"\/americas\/australias-orthocell-ready-to-file-on-interim-celgro-data\/","title":{"rendered":"Australia\u2019s Orthocell ready to file on interim Celgro\u2122 data"},"content":{"rendered":"

BioWorld has reported on Orthocell’s plans to seek early FDA approval for our Celgro\u2122 nerve regeneration treatment, following positive interim clinical results in quadriplegic patients.<\/p>\n

Read the article HERE.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

BioWorld has reported on Orthocell’s plans to seek early FDA approval for our Celgro\u2122 nerve regeneration treatment, following positive interim clinical results in quadriplegic patients.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2686","post","type-post","status-publish","format-standard","hentry","category-video"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t